Pelargonium Sidoides 1X and Its Impact on the Seasonal Cold

Sponsored by Integrative Therapeutics

Seasonal colds may pose significant socioeconomic challenges, affecting society and healthcare systems. Tackling these issues demands preventative actions and research into more effective interventions for symptom management.

There are a number of ways to curb the spread of the common cold, including masking and increased hygiene practices. An integrative homeopathic approach may be a solution to dealing with seasonal cold symptoms and reducing their duration.

About Pelargonium sidoides 1X

Pelargonium sidoides, commonly known as the South African geranium, is a flowering plant whose roots have long been used as a remedy for digestive issues and respiratory illness. The plant is thought to have antimicrobial properties, which is why modern research has supported its use as a popular homeopathic treatment for respiratory irritations and the common cold.

Proposed Mechanisms of Action

The chemical structure of the plant was discovered by German researchers in 1972.¹As further research was done, a proprietary active pharmaceutical ingredient EPs 7630(R) was developed in Europe.² EPs 7630 is a proprietary extract that has been the subject of over 20 clinical studies involving more than 9,000 patients. It has been an effective, well-tolerated, leading European phytomedicine for more than a decade.

In vitro studies suggest that the proposed mechanisms of action of EPs 7630 are multifactorial. EPs 7630 has immune cell stimulating activity and may promote an innate immune defense to eliminate foreign microbes quickly and efficiently.³ EPs 7630 promotes an increase in activity of monocytes, phagocytes⁴, and natural killer cells⁵, and stimulates the release of cytokines from cells.⁶

Pelargonium sidoides 1X has been shown to be safe for children and adults. Integrative Therapeutics’ V Clear is formulated with a homeopathic preparation of Pelargonium sidoides 1X (EPs 7630) and is available in a variety of formulations, including syrup, drops, and chewable tablets. For best results, use at first sign of symptoms and continue to use for an additional 48 hours after symptoms cease.

Conclusion

Clinical research behind EPs 7630 has advanced considerably in recent years and it continues to be a focus point of ongoing studies to reduce the duration and severity of the common cold. Several clinical trials have widely shown its role not only in reducing the nasal, chest and bronchial symptoms resulting from irritation of the airways, but also shortening the duration of illness to earlier resumption of usual activities in the patients affected.^7,8

Integrative Therapeutics creates exclusive products curated by clinicians, made with premium ingredients, and backed by science.

https://integrativepro.com/

REFERENCES